Bifidobacterium animalis subsp.lactis VB315 and use thereof

Abstract

Disclosed in the present invention is Bifidobacterium animalis subsp.lactis VB315, which is deposited in China General Microbiological Culture Collection Center on August 14, 2023, with the deposit number of CGMCC No. 28159. The Bifidobacterium animalis subsp.lactis VB315 of the present invention has a significant ability to produce butyric acid, can be used in the preparation of a drug for maintaining intestinal health, has relatively strong antibacterial ability and anticholinergic ability, and has great application prospects with regard to the preparation of medicines.

Description

Animal Bifidobacterium lactis subspecies VB315 and its application Technical Field

[0001] The present invention relates to the field of microorganisms, and in particular to animal Bifidobacterium lactis subspecies VB315 and applications thereof. Background Art

[0002] Bifidobacterium animalis subsp. lactis is a beneficial microorganism widely used in dairy and prebiotic products. It has an extremely high safety record and is listed on the "Generally Recognized As Safe" (GRAS) list of the U.S. Food and Drug Administration (FDA). The European Food Safety Authority (EFSA) has included this subspecies on its presumption of safety list. It is also listed on China's "List of Bacteria Acceptable for Food Use." It has been widely accepted and used in the food and pharmaceutical industries worldwide.

[0003] Short-chain fatty acids, particularly butyrate, play an essential role in maintaining intestinal health and contribute to the integrity of the intestinal mucosa. Current research indicates that butyrate has multiple protective effects on colonic wall cells, including: promoting epithelial growth and renewal, repairing intestinal mucosal damage; improving nutrient transport across the cell wall and regulating sodium and water absorption; promoting intestinal mucus protein secretion and strengthening the intestinal barrier function; reducing the absorption and harmful effects of enterotoxins such as ammonia, amines, indoles, and endotoxins; improving the intestinal lining's resistance to inflammation and oxidative stress; regulating the expression of antimicrobial peptides, exerting anti-inflammatory, antibacterial, and bactericidal effects; reducing excessive intestinal spasm and motility; inhibiting the formation of colonic adenomas and tumors; and lowering intestinal pH, which promotes the growth of anaerobic probiotics. Recent studies have shown that butyrate's beneficial effects extend beyond the colon, benefiting systemic and brain health. These benefits include nourishing brain nerves, aiding weight loss, controlling fatty liver disease, helping to lower blood sugar, and increasing skeletal muscle mass, making it a promising adjunctive therapy in clinical practice.

[0004] Relevant patents have reported that Bifidobacterium animalis subsp. lactis can increase the concentration of butyrate in feces, but this is not produced by the bacteria themselves. Instead, the bacteria increase butyrate production by cross-feeding with butyrate-producing bacteria in the colon. CN114164158B tested the contents of acetic acid, propionic acid, and butyric acid in the bacterial culture of Bifidobacterium animalis ZK-77, but the butyric acid concentration in the ZK-77 bacterial culture was low (only 0.562 mM), indicating that the industrial utilization value of this bacterium is limited.

[0005] Therefore, there is an urgent need for a Bifidobacterium animalis subsp. lactis that can increase butyrate production.

[0006] Summary of the Invention

[0007] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0008] To this end, the first aspect of the present invention provides a Bifidobacterium animalis subsp. lactis VB315, which is deposited in the General Microbiology Center of the China Culture Collection Administration on August 14, 2023, with a deposit number of CGMCC No. 28159.

[0009] The animal Bifidobacterium lactis subspecies provided by the present invention can produce butyric acid in high amounts, has the ability to inhibit Clostridium perfringens and Staphylococcus aureus, and also has excellent anticholine ability, gastric acid resistance and intestinal tolerance.

[0010] A second aspect of the present invention provides a fermentation supernatant, comprising the metabolites of the animal Bifidobacterium lactis subsp. VB315 described in the first aspect.

[0011] A third aspect of the present invention provides a bacterial suspension, comprising the animal Bifidobacterium lactis subsp. VB315 described in the first aspect.

[0012] The fourth aspect of the present invention provides use of the animal Bifidobacterium lactis subsp. VB315 described in the first aspect, the fermentation supernatant described in the second aspect, or the bacterial suspension described in the third aspect in the preparation of a medicament for maintaining intestinal health.

[0013] According to an embodiment of the present invention, the maintenance of intestinal health includes at least one of repairing intestinal mucosal damage, regulating the absorption of sodium and water by intestinal cell walls, enhancing intestinal barrier function, inhibiting the formation of colon adenomas and tumors, and antibacterial or bactericidal effects.

[0014] According to an embodiment of the present invention, maintaining intestinal health includes treating and / or preventing related diseases caused by at least one of Clostridium perfringens and Staphylococcus aureus.

[0015] The related diseases caused by Staphylococcus aureus and Clostridium perfringens include infectious diseases such as purulent abdominal infection, sepsis, endocarditis, diarrhea and fever.

[0016] The fifth aspect of the present invention provides a medicine comprising at least one of the animal Bifidobacterium lactis subsp. VB315 described in the first aspect, the fermentation supernatant described in the second aspect, and the bacterial suspension described in the third aspect.

[0017] According to an embodiment of the present invention, the medicament further contains an excipient and / or a carrier.

[0018] According to an embodiment of the present invention, the excipient includes at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent, and a sustained-release agent.

[0019] According to an embodiment of the present invention, the carrier includes at least one selected from sugars, cellulose and its derivatives, calcium phosphates, alkaline earth metal stearates, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols, and cereal hydrolyzed solids.

[0020] According to an embodiment of the present invention, the dosage form of the drug includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

[0021] According to an embodiment of the present invention, when Bifidobacterium animalis subsp. lactis VB315 functions, it may exist in the form of living cells or in the form of non-living cells.

[0022] According to an embodiment of the present invention, the living cells refer to cells with the ability to metabolize, reproduce or replicate, and the non-living cells refer to cells without the ability to metabolize, reproduce and replicate, including but not limited to dried bacteria (such as freeze-dried powder).

[0023] In addition, the present invention provides a microbial agent, comprising the aforementioned Bifidobacterium animalis subsp. lactis VB315, the aforementioned fermentation supernatant or the aforementioned bacterial suspension. The microbial agent of the present invention is used to maintain intestinal health.

[0024] The present invention also provides use of the aforementioned Bifidobacterium animalis subspecies lactis VB315 and / or the aforementioned fermentation supernatant in the preparation of health products and foods, wherein the health products or foods are used to maintain intestinal health.

[0025] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention.

[0026] Collection information:

[0027] Strain name: VB315

[0028] Deposit date: August 14, 2023

[0029] Depository: China General Microbiological Culture Collection Center (CGMCC)

[0030] Deposit number: CGMCC No.28159 BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments with reference to the following drawings, in which:

[0032] FIG1 shows the plate colony morphology of Bifidobacterium animalis subsp. lactis VB315 in Example 1 of the present invention.

[0033] FIG2 shows a log graph of a standard curve of butyric acid concentration-peak area determined by gas chromatography in Example 2 of the present invention.

[0034] FIG3 shows a gas chromatogram of the fermentation supernatant of Bifidobacterium animalis subsp. lactis VB315 in Example 2 of the present invention.

[0035] FIG4 shows the choline tolerance of Bifidobacterium animalis subsp. lactis VB315 in Example 4 of the present invention. DETAILED DESCRIPTION

[0036] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0037] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.

[0038] In this document, the terms “contain”, “include” or “include” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.

[0039] As used herein, the terms "optionally," "optional," or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0040] As used herein, "prevent" and "prevent" are used interchangeably. These terms refer to an approach for obtaining a beneficial or desired result, including but not limited to a prophylactic benefit. To obtain a "prophylactic benefit," Lactobacillus muciniphila ferments or a product containing the same can be administered to a subject at risk for developing a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have yet been made.

[0041] As used herein, the terms "treat" and "alleviate" refer to methods used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing a compound described herein to an individual in need.

[0042] In this article, "acceptable in health foods" refers to substances or compositions that can be consumed by humans, which may be adjusted according to the health food requirements of different countries.

[0043] As used herein, "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal to be treated therewith. Preferably, "pharmaceutically acceptable" as used herein means approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeia for use in animals, particularly humans.

[0044] As used herein, the term "pharmaceutically acceptable carrier" includes any solvent, pharmaceutical stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is encompassed.

[0045] In this article, the term "pharmaceutically acceptable excipients" may include sugars, including monosaccharides or polysaccharides, such as lactose, sucrose, mannitol and sorbitol; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and methyl cellulose; calcium phosphates, such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinyl pyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates, such as magnesium stearate and calcium stearate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; nonionic surfactants, cationic surfactants, anionic surfactants; ethylene glycol polymers; fatty alcohols; and cereal hydrolyzed solids and other non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, colorants, etc., which are commonly used excipients in pharmaceutical preparations.

[0046] According to a specific embodiment of the present invention, the present invention provides a Bifidobacterium animalis subsp. lactis VB315. According to an embodiment of the present invention, the deposit number of the Bifidobacterium animalis subsp. lactis is CGMCC No. 28159. The Bifidobacterium animalis subsp. lactis of the present invention has a significant butyrate production capacity and can be used to prepare drugs for maintaining intestinal health. It also has strong antibacterial, anticholinergic, gastric acid resistance, and intestinal tolerance, and has great application prospects in the preparation of pharmaceuticals.

[0047] As used herein, "Bifidobacterium animalis subsp. lactis VB315" and "Bifidobacterium animalis subsp. lactis VB315", "VB315" and "strain VB315" are synonymous.

[0048] The animal Bifidobacterium lactis subspecies VB315 obtained by screening in the present invention has a significant butyrate production ability compared with other animal Bifidobacterium lactis subspecies. According to a specific embodiment of the present invention, the strain VB315 of the present invention produces 339.9 ppm (equivalent to approximately 3.86 mM) of butyrate, which is much higher than other animal Bifidobacterium lactis subspecies.

[0049] The animal Bifidobacterium lactis subspecies VB315 obtained by screening in the present invention has the ability to inhibit Clostridium perfringens and Staphylococcus aureus compared with other animal Bifidobacterium lactis subspecies. In the test of inhibiting harmful bacteria, the bacteriostasis zone of the strain VB315 of the present invention for Clostridium perfringens is 19 mm, and the bacteriostasis zone of Staphylococcus aureus is 13 mm, showing strong antibacterial ability.

[0050] The present invention discloses a strain of Bifidobacterium animalis subsp. lactis VB315 that has a stronger choline resistance than other strains of Bifidobacterium animalis subsp. lactis. When treated for two hours at a bile salt concentration of 0.2%, the survival rate of the strain VB315 reaches 137%, and when treated for two hours at a bile salt concentration of 0.3%, the survival rate reaches 93%, with virtually no effect on the strain. Tests show that the strain VB315 has excellent choline resistance.

[0051] According to a specific embodiment of the present invention, a fermentation supernatant is provided, comprising: Bifidobacterium animalis subsp. lactis VB315 and / or metabolites of Bifidobacterium animalis subsp. lactis VB315. The Bifidobacterium animalis subsp. lactis of the present invention has strong antibacterial and anticholinergic abilities.

[0052] It should be noted that “fermentation supernatant” refers to the supernatant after centrifugation of the fermentation broth, which may contain Bifidobacterium animalis subsp. lactis VB315, or metabolites of Bifidobacterium animalis subsp. lactis VB315, or both Bifidobacterium animalis subsp. lactis VB315 and its metabolites.

[0053] According to a specific embodiment of the present invention, a microbial agent is provided, comprising the aforementioned Bifidobacterium animalis subsp. lactis VB315 and / or the aforementioned fermentation supernatant. The microbial agent of the present invention is used to prepare a drug for maintaining intestinal health and exhibits strong antibacterial, anticholinergic, gastric acid resistance, and intestinal tolerance, thus possessing significant application prospects in the preparation of pharmaceuticals.

[0054] It should be noted that the microbial agent of the present invention can be a liquid microbial agent, including but not limited to fermentation broth, etc.; it can also be a solid microbial agent, including but not limited to freeze-dried powder, etc.

[0055] According to an embodiment of the present invention, the Bifidobacterium animalis subsp. lactis VB315 exists in the form of living cells and / or non-living cells.

[0056] As used herein, "living cells" refer to cells that have the ability to metabolize, reproduce or replicate.

[0057] For example, the living cells may be immobilized cells. Herein, "immobilized cells" refer to Bifidobacterium animalis subsp. lactis VB315 immobilized on a carrier, which can carry out life activities such as growth, development, reproduction, inheritance and metabolism within a certain spatial range.

[0058] In this article, "non-viable cells" refer to cells that do not have the ability to metabolize, reproduce and replicate, including but not limited to dried bacteria. Exemplarily, the microbial agent is a freeze-dried powder.

[0059] As a specific embodiment, the Bifidobacterium animalis subspecies lactis VB315 exists in the form of living cells, dried bacteria, immobilized cells or any other forms.

[0060] As a specific embodiment, the dry bacteria are obtained by freeze-drying the animal Bifidobacterium lactis subspecies VB315.

[0061] According to an embodiment of the present invention, the present invention proposes a medicine or health product or food, which contains animal Bifidobacterium lactis subspecies VB315. Preferably, the medicine or health product or food of the present application is a live bacterial preparation for lowering cholesterol. It should be noted that the medicine or health product or food of the present application can be various preparations of active animal Bifidobacterium lactis subspecies VB315 alone, and can also be used in combination with other active ingredients, as long as they do not affect the activity of each other; further, the best case of the medicine or health product or food is that the active ingredients can have functional complementarity or a promoting effect, for example, animal Bifidobacterium lactis subspecies VB315 can be combined with other probiotics to make a composite probiotic tablet to achieve better or more active functions. Specifically, it can be determined according to the activity and components of the composite probiotic tablet, which is not limited here. Optionally, the medicine or health product or food further includes an acceptable carrier or excipient in the development of the medicine or health product or food. It should be noted that when preparing live bacteria preparations, carriers or excipients are usually required, as long as the added carriers or excipients do not inhibit each other or cause adverse side effects with Bifidobacterium animalis subsp. lactis VB315. The medicine, health product or food can be in the form of powder, tablet, beverage or capsule.

[0062] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.

[0063] Example 1: Strain collection and identification

[0064] Fresh feces (0.5 g) from healthy adults was added to 5 mL of Bifidobacterium BS liquid culture medium and cultured anaerobically at 37°C for 12-16 hours. The suspension was then homogenized and shaken to prepare a bacterial suspension. 1 mL of the suspension was then diluted to prepare different gradients of dilution. The suspension was then plated on MRS agar plates containing 0.05 g / 100 mL cysteine ​​and 5% serum (v / v). The suspension was then incubated anaerobically at 37°C for 48-72 hours. A total of 130 colonies with different morphologies were streaked and purified, and DNA was extracted. 16S rDNA was amplified by PCR using full-length 16S primers 27F and 1492R, and then sequenced. The corresponding strains were stored in glycerol tubes. The 16S sequencing results were compared by BLAST, and VB315 was ultimately identified and isolated.

[0065] The strain was named VB315 and was deposited in the General Microbiology Center of China Culture Collection Administration on August 14, 2023. The deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO.28159.

[0066] The biological characteristics of strain VB315 are as follows: Single colonies in solid culture are regularly round, 1-3 mm in diameter, white, and smooth, with a small white dot in the center (see Figure 1). 16S sequence analysis and BLAST comparison using NCBI indicated that strain VB315 is Bifidobacterium animalis subsp. lactis, a subspecies of Bifidobacterium animalis.

[0067] The sequence of strain VB315 is:

[0068] Example 2: Butyrate production test of VB315 strain

[0069] In an anaerobic workstation, a glycerol tube of Bifidobacterium animalis subsp. lactis VB315 was rethawed and inoculated at a 1% inoculum into a 20 mL / 250 mL culture medium containing: 0.5% peptone (BD), 0.5% beef extract, 1% tryptone, 0.5% yeast extract 860, 1% glucose, 0.1% Tween 80, 0.2% K₂HPO₄, 0.5% sodium acetate, 0.2% triammonium citrate, 0.025% ZnSO₄·7H₂O, and 0.01% MgSO₄·7H₂O. The pH was adjusted to 7.0. The culture was incubated at 37°C for 24 hours. The fermentation broth was centrifuged, and the supernatant was collected for gas chromatography.

[0070] Gas chromatography detection method and conditions are as follows: 2 mL of sample was pretreated with 10 μL of 10% phosphoric acid. The sample was analyzed using an Agilent 7890A gas chromatograph with a DB-624 capillary column (30 m x 0.32 mm x 1.8 μm). The column temperature was 100°C for 5 minutes, then increased at 10°C / min to 200°C, where it was held for 5 minutes. The injection port was set at 250°C, and the detector (FID) was set at 260°C. The injection volume was 1 μL, and the split ratio was 5:1. Headspace injection was used.

[0071] The logarithm of the standard curve of butyric acid concentration-peak area determined by gas chromatography is shown in FIG2 , the statistical results are shown in Table 1 , and the gas chromatogram of the fermentation supernatant of Bifidobacterium animalis subsp. lactis VB315 is shown in FIG3 .

[0072] Table 1: Gas chromatography determination of butyric acid concentration-peak area standard curve drawing table

[0073] The butyric acid concentration was calculated using the gas phase standard curve formula log(peak area)=1.2086×log(concentration)-3.2399. The calculation results showed that Bifidobacterium animalis subsp. lactis VB315 produced 339.9 ppm (equivalent to approximately 3.86 mM) of butyric acid.

[0074] Example 3: Test on inhibition of harmful bacteria by VB315 strain

[0075] The optimized double-layer plate culture method was used to study the inhibition of animal Bifidobacterium lactis subspecies VB315 on Clostridium perfringens and Staphylococcus aureus, including the following steps:

[0076] Preparation of Bifidobacterium animalis subsp. lactis VB315 in the lower layer: After thawing the activated single bacteria frozen tube, inoculate it into an MRS plate with a pH of 6.9 (inoculation volume: 2 μL / point), and culture it anaerobically at 37°C for 1 day. The culture medium is MRS (purchased from Guangdong Huankai Biotechnology Co., Ltd.) + agar 1.8%.

[0077] Preparation of the upper pathogenic bacteria layer: The sterilized Clostridium perfringens culture medium was cooled to 40-50℃, and Clostridium perfringens was inoculated to make the final concentration of the culture medium about 10 6 CFU / mL, mix well. Add 7mL / plate of the culture medium to a plate that has grown Bifidobacterium animalis subsp. lactis VB315. After solidification, culture anaerobically at 37℃ for 1 day. The culture medium is composed of 1.5% tryptone, 0.3% beef extract, 0.5% sodium chloride, 1% glucose, and 0.5% agar. Adjust the pH to 7.0. Cool the sterilized LB culture medium to 40-50℃ and inoculate Staphylococcus aureus to a final concentration of about 10 6 CFU / mL, mix well. Add 7mL / plate of the culture medium to a plate with Bifidobacterium animalis subsp. lactis VB315 grown. After solidification, culture aerobically at 37°C for 1 day. The culture medium is LB medium, 0.5% agar, and the pH is adjusted to 7.0.

[0078] After the upper plate has grown, observe whether there is an inhibition zone around animal Bifidobacterium lactis subsp. VB315 to determine whether it has antibacterial ability.

[0079] Table 2: Antibacterial experiment of strain VB315

[0080] As can be seen from Table 2, animal Bifidobacterium lactis subspecies VB315 has the ability to inhibit Clostridium perfringens and Staphylococcus aureus.

[0081] Example 4: Choline resistance test of VB315 strain

[0082] The viable count reached about 10 9 -10 10 CFU / mL glycerol tubes were used as samples to investigate the tolerance of animal Bifidobacterium lactis subspecies VB315 to different bile salt concentrations. The bile salt concentrations were 0.06%, 0.1%, 0.2%, and 0.3%, respectively. The treatment time was 2 and 4 hours, and the survival rate was detected by dilution and smearing.

[0083] To prepare artificial pancreatic juice: Prepare a 1% sodium chloride solution with normal saline (sodium chloride: 0.9%). Add taurine choline at concentrations of 0.06%, 0.1%, 0.2%, and 0.3%, to a volume of 30 mL / bottle. Sterilize at 121°C for 30 minutes. Add 0.1% trypsin (prepare a 1% concentration, filter through a sterile membrane, and add to normal saline at a ratio of 1:9).

[0084] Preparation of bacterial suspension: Take the viable bacteria count to about 10 9 -10 10 The probiotic suspension with a CFU / mL was prepared into a glycerol tube and frozen in a -80℃ refrigerator for later use.

[0085] Take 9 mL of artificial pancreatic juice at 0.06%, 0.1%, 0.2%, or 0.3% concentrations and add 1 mL of 1% trypsin. Then, aliquot 990 μL of each pancreatic juice into 1.5 mL EP tubes and label them. Add 10 μL of the thawed bacterial suspension from the glycerol tube to each EP tube and mix thoroughly. Incubate at 37°C for 2 and 4 hours, then remove the tubes and spread them for counting. Simultaneously perform a control: Add 10 μL of the bacterial suspension to 990 μL of sterile water, mix thoroughly, and spread them for counting.

[0086] The results are shown in Table 3 and the schematic diagram is shown in Figure 4, which shows that when treated for 2 hours at a bile salt concentration of 0.2%, the survival rate reached 137%, and when treated for 2 hours at a bile salt concentration of 0.3%, the survival rate reached 93%, with basically no effect on the strain. The experiment shows that the VB315 strain has a good anticholinergic ability.

[0087] Table 3: Choline resistance test of strain VB315

[0088] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0089] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A Bifidobacterium animalis subsp. lactis VB315, characterized in that The deposit number of the Bifidobacterium animalis subsp. lactis VB315 is CGMCC No.28159.

2. A fermentation supernatant, characterized in that: The invention comprises the metabolites of the animal Bifidobacterium lactis subspecies VB315 as described in claim 1.

3. A bacterial suspension, characterized in that: It includes the animal Bifidobacterium lactis subspecies VB315 described in claim 1.

4. Use of the animal Bifidobacterium lactis subspecies VB315 according to claim 1, the fermentation supernatant according to claim 2 or the bacterial suspension according to claim 3 in the preparation of a medicament for maintaining intestinal health.

5. The use according to claim 4, characterized in that The maintenance of intestinal health includes at least one of repairing intestinal mucosal damage, regulating the absorption of sodium and water by intestinal cell walls, enhancing intestinal barrier function, inhibiting the formation of colon adenomas and tumors, and antibacterial or bactericidal effects.

6. The use according to claim 4, characterized in that The maintaining of intestinal health includes treating and / or preventing related diseases caused by at least one of Clostridium perfringens and Staphylococcus aureus.

7. A drug, characterized in that The drug comprises at least one of the animal Bifidobacterium lactis subspecies VB315 described in claim 1, the fermentation supernatant described in claim 2, and the bacterial suspension described in claim 3.

8. The drug according to claim 7, characterized in that The medicament further contains excipients and / or carriers.

9. The drug according to claim 8, characterized in that The excipient comprises at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent, and a sustained-release agent.

10. The drug according to claim 8, characterized in that The carrier comprises at least one selected from sugars, cellulose and its derivatives, calcium phosphates, stearic acid alkaline earth metal salts, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols, and cereal hydrolyzed solids.

11. The drug according to claim 7, characterized in that The dosage form of the drug includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

Images